Robella, M.; De Simone, M.; Berchialla, P.; Argenziano, M.; Borsano, A.; Ansari, S.; Abollino, O.; Ficiarà , E.; Cinquegrana, A.; Cavalli, R.;
et al. A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis. Cancers 2021, 13, 1060.
https://doi.org/10.3390/cancers13051060
AMA Style
Robella M, De Simone M, Berchialla P, Argenziano M, Borsano A, Ansari S, Abollino O, Ficiarà E, Cinquegrana A, Cavalli R,
et al. A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis. Cancers. 2021; 13(5):1060.
https://doi.org/10.3390/cancers13051060
Chicago/Turabian Style
Robella, Manuela, Michele De Simone, Paola Berchialla, Monica Argenziano, Alice Borsano, Shoeb Ansari, Ornella Abollino, Eleonora Ficiarà , Armando Cinquegrana, Roberta Cavalli,
and et al. 2021. "A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis" Cancers 13, no. 5: 1060.
https://doi.org/10.3390/cancers13051060
APA Style
Robella, M., De Simone, M., Berchialla, P., Argenziano, M., Borsano, A., Ansari, S., Abollino, O., Ficiarà , E., Cinquegrana, A., Cavalli, R., & Vaira, M.
(2021). A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis. Cancers, 13(5), 1060.
https://doi.org/10.3390/cancers13051060
